Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
Clinical trial NCT04139317 · TERMINATED
Trial details
- NCT number
- NCT04139317
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-22
- Primary completion
- 2022-01-14
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.